More than 60 percent of breast cancer cases involve defects in the same biochemical chain of events within cancer cells-- known as the PI3 kinase (PI3K) pathway--but efforts to develop therapies targeting this pathway have met with little success after hundreds of mostly failed clinical trials. And researchers still don't understand why.
More...